Form 4: Elevance Health Director Deanna Strable-Soethout Reports Acquisition of Deferred Stock Units

Deanna Strable-Soethout, a director of Elevance Health, Inc., reported the acquisition of deferred stock units under the company's Board of Directors Compensation Program.

Summary

• On May 15, 2024, Deanna Strable-Soethout, a director of Elevance Health, Inc., acquired 388 deferred stock units.
• These units were accrued under the Elevance Health, Inc. Board of Directors Compensation Program.
• The deferred stock units are payable in Company common stock upon the earlier of (a) five years from the grant date or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated.
• Following the transaction, Ms. Strable-Soethout directly owns 1,045 shares of Elevance Health common stock.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing indicating standard compensation practices. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Positives

• The acquisition of deferred stock units aligns the director's interests with the long-term performance of Elevance Health.
• The vesting conditions encourage continued service on the board of directors.

Future Outlook

The deferred stock units will be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.

Industry Context

This Form 4 filing is a routine disclosure related to director compensation and is typical for publicly traded companies like Elevance Health. It provides transparency into the equity holdings of company insiders.

Comparison to Industry Standards

• Director compensation packages often include deferred stock units to align director interests with shareholder value, similar to practices at UnitedHealth Group (UNH) and CVS Health (CVS).
• The vesting schedule of five years or upon leaving the board is a common structure, comparable to arrangements at other large healthcare companies like Humana (HUM).

Stakeholder Impact

• Shareholders can view this as a positive sign that directors have a vested interest in the company's long-term success.
• Employees may see this as a standard part of executive compensation.

Key Dates